IFN-γ-induced TNFR2 expression is required for TNF-dependent intestinal epithelial barrier dysfunction

被引:259
作者
Wang, Fengjun
Schwarz, Brad T.
Graham, W. Vallen
Wang, Yingmin
Su, Liping
Clayburgh, Daniel R.
Abraham, Clara
Turner, Jerrold R.
机构
[1] Univ Chicago, Dept Pathol, Chicago, IL 60637 USA
[2] Univ Chicago, Dept Med, Chicago, IL 60637 USA
[3] Third Mil Med Univ, SW Hosp, Inst Burn Res, State Key Lab Trauma Burns & Combined Injury, Chongqing, Peoples R China
关键词
D O I
10.1053/j.gastro.2006.08.022
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: Tumor necrosis factor (TNF) plays a critical role in intestinal disease. In intestinal epithelia, TNF causes tight junction disruption and epithelial barrier loss by up-regulating myosin light chain kinase (MLCK) activity and expression. The aim of this study was to determine the signaling pathways by which TNF causes intestinal epithelial barrier loss. Methods: Caco-2 cells that were either nontransfected or stably transfected with human TNF receptor 1 (TNFR1) or TNFR2 and mouse colonocytes were used for physiologic, morphologic, and biochemical analyses. Results: Colitis induced in vivo by adoptive transfer of CD4(+)CD45RB(hi) T cells was associated with increased epithelial MLCK expression and myosin II regulatory light chain (MLC) phosphorylation as well as morphologic tight junction disruption. In vitro studies showed that TNF caused similar increases in MLCK expression and MLC phosphorylation, as well as barrier dysfunction, in Caco-2 monolayers only after interferon (IFN)-gamma pretreatment. This reductionist model was therefore used to determine the molecular mechanism by which IFN-gamma and TNF synergize to cause intestinal epithelial barrier loss. IFN-gamma priming increased TNFR1 and TNFR2 expression, and blocking antibody studies showed that TNFR2, but not TNFR1, was required for TNF-induced barrier dysfunction. Transgenic TNFR2, but not TNFR1, expression allowed IFN-gamma-independent TNF responses. Conclusions: IFN-gamma primes intestinal epithelia to respond to TNF by inducing TNFR2 expression, which in turn mediates TNF-induced MLCK-dependent barrier dysfunction. The data further suggest that epithelial TNFR2 blockade may be a novel approach to restore barrier function in intestinal disease.
引用
收藏
页码:1153 / 1163
页数:11
相关论文
共 57 条
  • [1] Infliximab downregulates interferon-γ production in activated gut T-lymphocytes from patients with Crohn's disease
    Agnholt, J
    Kaltoft, K
    [J]. CYTOKINE, 2001, 15 (04) : 212 - 222
  • [2] A murine transmembrane tumor necrosis factor (TNF) transgene induces arthritis by cooperative p55/p75 TNF receptor signaling
    Alexopoulou, L
    Pasparakis, M
    Kollias, G
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 1997, 27 (10) : 2588 - 2592
  • [3] Arnott IDR, 2000, SCAND J GASTROENTERO, V35, P1163
  • [4] Berglund JJ, 2001, AM J PHYSIOL-GASTR L, V281, pG1487
  • [5] Epithelial myosin light chain kinase expression and activity are upregulated in inflammatory bowel disease
    Blair, SA
    Kane, SV
    Clayburgh, DR
    Turner, JR
    [J]. LABORATORY INVESTIGATION, 2006, 86 (02) : 191 - 201
  • [6] TNF-TNFR2 interactions are critical for the development of intestinal graft-versus-host disease in MHC class II-disparate (C57BL/6J→C57BL/6J x bm12)F1 mice
    Brown, GR
    Lee, E
    Thiele, DL
    [J]. JOURNAL OF IMMUNOLOGY, 2002, 168 (06) : 3065 - 3071
  • [7] Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms
    Bruewer, M
    Luegering, A
    Kucharzik, T
    Parkos, CA
    Madara, JL
    Hopkins, AM
    Nusrat, A
    [J]. JOURNAL OF IMMUNOLOGY, 2003, 171 (11) : 6164 - 6172
  • [8] Epithelial myosin light chain kinase-dependent barrier dysfunction mediates T cell activation-induced diarrhea in vivo
    Clayburgh, DR
    Barrett, TA
    Tang, YM
    Meddings, JB
    Van Eldik, LJ
    Watterson, DM
    Clarke, LL
    Mrsny, RJ
    Turner, JR
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (10) : 2702 - 2715
  • [9] A porous defense: the leaky epithelial barrier in intestinal disease
    Clayburgh, DR
    Shen, L
    Turner, JR
    [J]. LABORATORY INVESTIGATION, 2004, 84 (03) : 282 - 291
  • [10] COLGAN SP, 1994, AM J PHYSIOL, V267, P402